Ulipristal acetate does not impact human normal breast tissue

Human Reproduction

Volumn 27, Issue 9, 2012, Pages 2785-2798

  Communal, Laudine ^a   Vilasco, Myriam ^a   Hugon Rodin, Justine ^a,b   Courtin, Aurélie ^a   Mourra, Najat ^a   Lahlou, Najiba ^c   Dumont, Sylvie ^a   Chaouat, Marc ^c   Forgez, Patricia ^a   Gompel, Anne ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b Cochin ^*  (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

BCL2; cyclin A; FASN; IEX 1; Ki67

Indexed keywords

ALKALINE PHOSPHATASE; CYCLIN A; DEXAMETHASONE; ESTRADIOL; FATTY ACID SYNTHASE; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; ULIPRISTAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MITOSIS INDEX; MOUSE; NONHUMAN; REPORTER GENE; TRANSACTIVATION; XENOGRAFT;

EID: 84864919313     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/des221     Document Type: Article

References (79)

1. Anderson E. Ovarian steroids and control of proliferation in the normal human breast. Breast 2001;10:273-278. (Pubitemid 32694500)
2. Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002; 188:111-123. (Pubitemid 34242671)
3. Attardi BJ, Burgenson J, Hild SA, Reel JR. In vitro antiprogestational/ antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol 2004;88:277-288. (Pubitemid 38553759)
4. Bakker GH, Setyono-Han B, Henkelman MS, de Jong FH, Lamberts SW, van der Schoot P, Klijn JG. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treatment Reports 1987;71:1021-1027. (Pubitemid 18002209)
5. Bardon S, Vignon F, Chalbos D, Rochefort H. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J Clin Endocrinol Metab 1985;60:692-697. (Pubitemid 15147555)
6. Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 2003;68:1013-1017. (Pubitemid 37532426)
7. Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 1997;2:323-334.
8. Brenner RM, Slayden OD, Nath A, Tsong YY, Sitruk-Ware R. Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception 2010;81:336-342.
9. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997;48:129-156. (Pubitemid 27101820)
10. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307. (Pubitemid 40674206)
11. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92:3582-3589. (Pubitemid 47435338)
12. Chalbos D, Joyeux C, Galtier F, Rochefort H. Progestin-induced fatty acid synthetase in human mammary tumors: from molecular to clinical studies. J Steroid Biochem Mol Biol 1992;43:223-228.
13. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454-457.
14. Clarke RB, Howell A, Anderson E. Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res Treat 1997;45:121-133. (Pubitemid 27399960)
15. Cook CE, Lee YW, Wani MC, Fail PA, Petrow V. Effects of D-ring substituents on antiprogestational (antagonist) and progestational (agonist) activity of 11 beta-aryl steroids. Hum Reprod 1994;9 Suppl 1:32-39. (Pubitemid 24203925)
16. Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat AM, Chaouat M, Forgez P et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 2012;131:49-63.
17. Dannecker C, Possinger K, Classen S. Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D. Ann Oncol 1996;7:391-395. (Pubitemid 26246791)
18. Di Lorenzo D, Gianni M, Savoldi GF, Ferrari F, Albertini A, Garattini E. Progesterone induced expression of alkaline phosphatase is associated with a secretory phenotype in T47D breast cancer cells. Biochem Biophys Res Commun 1993;192:1066-1072. (Pubitemid 23218523)
19. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227-233. (Pubitemid 40800387)
20. Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod 2008; 23:2072-2079.
21. Esteve JL, Acosta R, Perez Y, Campos R, Hernandez AV, Texido CS. Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol 2012;161:202-208.
22. Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S, de Lignieres B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-969. (Pubitemid 28193936)
23. Gabet Y, Noh T, Lee C, Frenkel B. Developmentally regulated inhibition of cell cycle progression by glucocorticoids through repression of cyclin A transcription in primary osteoblast cultures. J Cell Physiol 2011; 226:991-998.
24. Gainer EE, Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids 2003;68:1005-1011. (Pubitemid 37532425)
25. Gompel A, Malet C, Spritzer P, Lalardrie JP, Kuttenn F, Mauvais-Jarvis P. Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63:1174-1180. (Pubitemid 17173057)
26. Gompel A, Somai S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M, Rostene W. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000;65:593-598.
27. Goyeneche AA, Seidel EE, Telleria CM. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Invest New Drugs 2012;30:967-980.
28. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18:502-519. (Pubitemid 27349554)
29. Hild SA, Reel JR, Hoffman LH, Blye RP. CDB-2914: anti-progestational/ anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod 2000;15:822-829. (Pubitemid 30192730)
30. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995;377:397-404.
31. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 1996;24:899-905. (Pubitemid 26274749)
32. Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator. Breast Cancer Res Treat 2003;78:193-204. (Pubitemid 36433912)
33. Jang GR, Wrighton SA, Benet LZ. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol 1996;52:753-761. (Pubitemid 26276491)
34. Joyeux C, Chalbos D, Rochefort H. Effects of progestins and menstrual cycle on fatty acid synthetase and progesterone receptor in human mammary glands. J Clin Endocrinol Metab 1990;70:1438-1444.
35. Kandouz M, Siromachkova M, Jacob D, Chretien Marquet B, Therwath A, Gompel A. Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. Int J Cancer 1996;68:120-125. (Pubitemid 26354589)
36. Kehrl JH, Sinnarajah S. RGS2: a multifunctional regulator of G-protein signaling. Int J Biochem Cell Biol 2002;34:432-438. (Pubitemid 34242757)
37. Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 2004;160:825-841. (Pubitemid 39434767)
38. Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 1989;49:2851-2856. (Pubitemid 19148614)
39. Klijn JG, Setyono-Han B, Sander HJ, Lamberts SW, de Jong FH, Deckers GH, Foekens JA. Pre-clinical and clinical treatment of breast cancer with antiprogestins. Hum Reprod 1994;9 Suppl 1:181-189. (Pubitemid 24203940)
40. Klijn JG, Setyono-Han B, Foekens JA. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000;65:825-830.
41. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006;66:5977-5980.
42. Leminen R, Raivio T, Ranta S, Oehler J, von Hertzen H, Janne OA, Heikinheimo O. Late follicular phase administration of mifepristone suppresses circulating leptin and FSH - mechanism(s) of action in emergency contraception? Eur J Endocrinol 2005;152:411-418. (Pubitemid 40439494)
43. Leo JC, Lin VC. The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene-selective manner. Int J Cancer 2008;122:230-243. (Pubitemid 350210000)
44. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, Blocker W, Nieman LK. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129-1136. (Pubitemid 351620347)
45. Li X, Wong J, Tsai SY, Tsai MJ, O'Malley BW. Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 2003;23:3763-3773. (Pubitemid 36597457)
46. Li LB, Louie MC, Chen HW, Zou JX. Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett 2008;261:64-73.
47. Lin VC, Ng EH, Aw SE, Tan MG, Chan VS, Ho GH. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 1999;5:395-403. (Pubitemid 29085193)
48. Lin VC, Woon CT, Aw SE, Guo C. Distinct molecular pathways mediate progesterone-induced growth inhibition and focal adhesion. Endocrinology 2003;144:5650-5657. (Pubitemid 37476094)
49. Liu Z, Auboeuf D, Wong J, Chen JD, Tsai SY, Tsai MJ, O'Malley BW. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci USA 2002;99:7940-7944. (Pubitemid 34650984)
50. Longacre TA, Bartow S.A. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382-393. (Pubitemid 16066440)
51. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266-2278.
52. Malet C, Gompel A, Yaneva H, Cren H, Fidji N, Mowszowicz I, Kuttenn F, Mauvais-Jarvis P. Estradiol and progesterone receptors in cultured normal human breast epithelial cells and fibroblasts: immunocytochemical studies. J Clin Endocrinol Metab 1991;73:8-17. (Pubitemid 21901093)
53. Marions L, Hultenby K, Lindell I, Sun X, Stabi B, Gemzell Danielsson K. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol 2002;100:65-71. (Pubitemid 34722844)
54. Maruo T, Ohara N, Yoshida S, Nakabayashi K, Sasaki H, Xu Q, Chen W, Yamada H. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system. Contraception 2010;82:435-441.
55. Murkes D, Conner P, Leifland K, Tani E, Beliard A, Lundström E, Söderqvist G. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188-1191.
56. Nieman LK, BlockerW, Nansel T, Mahoney S, Reynolds J, Blithe D,Wesley R, Armstrong A. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebocontrolled, phase IIb study. Fertil Steril 2011;95:767-772 e761-762.
57. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-1357.
58. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-1470. (Pubitemid 44871955)
59. Ramakrishnan R, Khan SA, Badve S. Morphological changes in breast tissue with menstrual cycle. Mod Pathol 2002;15:1348-1356. (Pubitemid 35463004)
60. Reel JR, Hild-Petito S, Blye RP. Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple, or continuous doses to rats. Contraception 1998;58:129-136. (Pubitemid 28449367)
61. Ritzke C, Stieber P, Untch M, Nagel D, Eiermann W, Fateh-Moghadam A. Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases. Anticancer Res 1998;18:1243-1249. (Pubitemid 28234024)
62. Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 1987;74:455-461. (Pubitemid 17135278)
63. Schneider MR, Michna H, Habenicht UF, Nishino Y, Grill HJ, Pollow K. The tumour-inhibiting potential of the progesterone antagonist Onapristone in the human mammary carcinoma T61 in nude mice. J Cancer Res Clin Oncol 1992;118:187-189.
64. Sengupta S, Vonesch JL, Waltzinger C, Zheng H, Wasylyk B. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J 2000;19:6051-6064.
65. Shen L, Guo J, Santos-Berrios C, Wu MX. Distinct domains for anti- and pro-apoptotic activities of IEX-1. J Biol Chem 2006;281:15304-15311. (Pubitemid 43855120)
66. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004;25:45-71. (Pubitemid 38292038)
67. Soderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123-128. (Pubitemid 127780760)
68. Spitz IM, Croxatto HB, Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol 1996;36:47-81. (Pubitemid 26168694)
69. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 1996;15:3667-3675. (Pubitemid 26239779)
70. Wagner BL, Pollio G, Leonhardt S, Wani MC, Lee DY, Imhof MO, Edwards DP, Cook CE, McDonnell DP. 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc Natl Acad Sci USA 1996;93:8739-8744. (Pubitemid 26269630)
71. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 1998;18:1369-1378. (Pubitemid 28100901)
72. Wagner BL, Pollio G, Giangrande P, Webster JC, Breslin M, Mais DE, Cook CE, Vedeckis WV, Cidlowski JA, McDonnell DP. The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins. Endocrinology 1999;140:1449-1458. (Pubitemid 29104252)
73. Wan Y, Nordeen SK. Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells. Mol Endocrinol 2002;16:1204-1214. (Pubitemid 34621070)
74. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125-134. (Pubitemid 46115419)
75. Wood CE, Register TC, Cline JM. Transcriptional profiles of progestogen effects in the postmenopausal breast. Breast Cancer Res Treat 2009; 114:233-242.
76. Wu MX. Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. Apoptosis 2003;8:11-18. (Pubitemid 36133133)
77. Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson ED, Maruo T. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005;90:953-961. (Pubitemid 40279221)
78. Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, Johansson ED, Maruo T. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006; 21:2408-2416. (Pubitemid 44530620)
79. Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, Sasaki H, Morikawa A, Maruo T. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010;28:260-273.